CBD's pharmacology is complex and NOT primarily mediated through cannabinoid receptors: (1) 5-HT1A partial agonist, the serotonin receptor responsible for CBD's anxiolytic effects (same receptor targeted by buspirone); (2) TRPV1 agonist, vanilloid receptor activation, desensitization → pain modulation; (3) GPR55 antagonist, orphan cannabinoid receptor involved in cancer cell proliferation; (4) Allosteric modulator of CB1, does NOT directly activate CB1 (that's THC) but modulates its signaling; (5) Adenosine reuptake inhibition, increases extracellular adenosine (anti-inflammatory, neuroprotective); (6) PPARγ agonist, nuclear receptor activation for anti-inflammatory effects; (7) CYP3A4 and CYP2C19 inhibition, MAJOR drug interaction mechanism.
Independently graded against 178,763 indexed supplements and 757 reviewed supplement and medication pairs, sourced from PubMed, FDA CAERS, openFDA, and NIH DSLD | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.